论文部分内容阅读
目的观察多西他赛(Taxotere)和草酸铂(L-OHP)联合化疗双周方案治疗晚期非小细胞肺癌(non-smallcelllungcancer,NSCLC)的疗效和毒副反应。方法51例NSCLC患者(初治16例,复治35例;ⅢB期19例,Ⅳ期32例)应用化疗方案为多西他赛60mg/m2,静脉滴入,d1、d15;草酸铂100mg/m2,静脉滴入,d1、d15。两周为1个周期,均采用4个周期以上评价疗效及毒副反应。结果51例患者均可评价疗效,共完成358个周期化疗。完全缓解1例,部分缓解18例,总有效率37.3%;其中初治者有效率56.3%,复治者为31.4%;ⅢB期有效率57.9%,Ⅳ期为25.0%。中位缓解期5.6个月,中位生存期11.5个月。主要毒副反应为骨髓抑制和外周神经炎。结论多西他赛联合草酸铂双周化疗方案对晚期NSCLC有较好的疗效和可以耐受的毒副反应。
Objective To observe the curative effect and toxicity of docetaxel (Taxotere) combined with oxaliplatin (L-OHP) in combination with two-week regimen in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Fifty-one patients with NSCLC (initial treatment 16, retreatment 35; stage Ⅲ B 19, stage Ⅳ Ⅳ) were treated with docetaxel 60mg / m2, intravenous infusion, d1, d15 and oxaliplatin 100mg / m2, intravenous infusion, d1, d15. Two weeks for a cycle, are used more than four cycles evaluation of efficacy and side effects. Results All the 51 patients could evaluate the curative effect and completed 358 cycles of chemotherapy. Complete remission in 1 case, partial remission in 18 cases, the total effective rate was 37.3%; of which 56.3% were effective in primary treatment, re-treatment was 31.4%; Ⅲ B 57.9% effective rate, Ⅳ stage 25.0%. The median remission was 5.6 months, with a median survival of 11.5 months. The main toxicities are myelosuppression and peripheral neuritis. Conclusion Docetaxel combined with oxaliplatin bi-weekly chemotherapy has better efficacy and tolerable side effects on advanced NSCLC.